154 related articles for article (PubMed ID: 34178676)
1. LLGL2 Increases Ca
Leng S; Xie F; Liu J; Shen J; Quan G; Wen T
Front Oncol; 2021; 11():683629. PubMed ID: 34178676
[TBL] [Abstract][Full Text] [Related]
2. LLGL2 rescues nutrient stress by promoting leucine uptake in ER
Saito Y; Li L; Coyaud E; Luna A; Sander C; Raught B; Asara JM; Brown M; Muthuswamy SK
Nature; 2019 May; 569(7755):275-279. PubMed ID: 30996345
[TBL] [Abstract][Full Text] [Related]
3. Activation of PI3K/AKT is involved in TINAG-mediated promotion of proliferation, invasion and migration of hepatocellular carcinoma.
Zhang MH; Niu H; Li Z; Huo RT; Wang JM; Liu J
Cancer Biomark; 2018; 23(1):33-43. PubMed ID: 29991125
[TBL] [Abstract][Full Text] [Related]
4. The long non-coding RNA PTTG3P promotes cell growth and metastasis via up-regulating PTTG1 and activating PI3K/AKT signaling in hepatocellular carcinoma.
Huang JL; Cao SW; Ou QS; Yang B; Zheng SH; Tang J; Chen J; Hu YW; Zheng L; Wang Q
Mol Cancer; 2018 May; 17(1):93. PubMed ID: 29803224
[TBL] [Abstract][Full Text] [Related]
5. SPAG5 interacts with CEP55 and exerts oncogenic activities via PI3K/AKT pathway in hepatocellular carcinoma.
Yang YF; Zhang MF; Tian QH; Fu J; Yang X; Zhang CZ; Yang H
Mol Cancer; 2018 Aug; 17(1):117. PubMed ID: 30089483
[TBL] [Abstract][Full Text] [Related]
6. Silencing of LLGL2 Suppresses the Estradiol-Induced BPH-1 Cell Proliferation through the Regulation of Autophagy.
Kim KH; Hong GL; Kim YJ; Lee HJ; Jung JY
Biomedicines; 2022 Aug; 10(8):. PubMed ID: 36009528
[TBL] [Abstract][Full Text] [Related]
7.
Gu QY; Liu YX; Wang JL; Huang XL; Li RN; Linghu H
Cancers (Basel); 2023 Dec; 15(24):. PubMed ID: 38136424
[TBL] [Abstract][Full Text] [Related]
8. Mammalian Llgl2 is necessary for proper branching morphogenesis during placental development.
Sripathy S; Lee M; Vasioukhin V
Mol Cell Biol; 2011 Jul; 31(14):2920-33. PubMed ID: 21606200
[TBL] [Abstract][Full Text] [Related]
9. Sema3d Restrained Hepatocellular Carcinoma Progression Through Inactivating Pi3k/Akt Signaling
Li Y; Xu C; Sun B; Zhong F; Cao M; Yang L
Front Oncol; 2022; 12():913498. PubMed ID: 35957887
[TBL] [Abstract][Full Text] [Related]
10. CircCCNB1 silencing acting as a miR-106b-5p sponge inhibited GPM6A expression to promote HCC progression by enhancing DYNC1I1 expression and activating the AKT/ERK signaling pathway.
Liu YM; Cao Y; Zhao PS; Wu LY; Lu YM; Wang YL; Zhao JF; Liu XG
Int J Biol Sci; 2022; 18(2):637-651. PubMed ID: 35002514
[No Abstract] [Full Text] [Related]
11. PRMT4 promotes hepatocellular carcinoma progression by activating AKT/mTOR signaling and indicates poor prognosis.
Du P; Luo K; Li G; Zhu J; Xiao Q; Li Y; Zhang X
Int J Med Sci; 2021; 18(15):3588-3598. PubMed ID: 34522186
[No Abstract] [Full Text] [Related]
12. Effect of nicastrin on hepatocellular carcinoma proliferation and apoptosis through PI3K/AKT signalling pathway modulation.
Wang X; Wang X; Xu Y; Yan M; Li W; Chen J; Chen T
Cancer Cell Int; 2020; 20():91. PubMed ID: 32226312
[TBL] [Abstract][Full Text] [Related]
13. ADORA1 Promotes Hepatocellular Carcinoma Progression via PI3K/AKT Pathway.
Ni S; Wei Q; Yang L
Onco Targets Ther; 2020; 13():12409-12419. PubMed ID: 33293832
[TBL] [Abstract][Full Text] [Related]
14. MCM6 promotes metastasis of hepatocellular carcinoma via MEK/ERK pathway and serves as a novel serum biomarker for early recurrence.
Liu M; Hu Q; Tu M; Wang X; Yang Z; Yang G; Luo R
J Exp Clin Cancer Res; 2018 Jan; 37(1):10. PubMed ID: 29357919
[TBL] [Abstract][Full Text] [Related]
15. MicroRNA-155-5p promotes hepatocellular carcinoma progression by suppressing PTEN through the PI3K/Akt pathway.
Fu X; Wen H; Jing L; Yang Y; Wang W; Liang X; Nan K; Yao Y; Tian T
Cancer Sci; 2017 Apr; 108(4):620-631. PubMed ID: 28132399
[TBL] [Abstract][Full Text] [Related]
16. miR-300 regulates the epithelial-mesenchymal transition and invasion of hepatocellular carcinoma by targeting the FAK/PI3K/AKT signaling pathway.
Wang R; Yu Z; Chen F; Xu H; Shen S; Chen W; Chen L; Su Q; Zhang L; Bi J; Zeng W; Li W; Huang X; Wang Q
Biomed Pharmacother; 2018 Jul; 103():1632-1642. PubMed ID: 29864952
[TBL] [Abstract][Full Text] [Related]
17. MicroRNA-1296 inhibits metastasis and epithelial-mesenchymal transition of hepatocellular carcinoma by targeting SRPK1-mediated PI3K/AKT pathway.
Xu Q; Liu X; Liu Z; Zhou Z; Wang Y; Tu J; Li L; Bao H; Yang L; Tu K
Mol Cancer; 2017 Jun; 16(1):103. PubMed ID: 28606154
[TBL] [Abstract][Full Text] [Related]
18. CLCA4 inhibits cell proliferation and invasion of hepatocellular carcinoma by suppressing epithelial-mesenchymal transition via PI3K/AKT signaling.
Liu Z; Chen M; Xie LK; Liu T; Zou ZW; Li Y; Chen P; Peng X; Ma C; Zhang WJ; Li PD
Aging (Albany NY); 2018 Oct; 10(10):2570-2584. PubMed ID: 30312171
[TBL] [Abstract][Full Text] [Related]
19. miR-3691-5p promotes hepatocellular carcinoma cell migration and invasion through activating PI3K/Akt signaling by targeting PTEN.
Du W; Zhang X; Wan Z
Onco Targets Ther; 2019; 12():4897-4906. PubMed ID: 31417285
[No Abstract] [Full Text] [Related]
20. Increased dopamine and its receptor dopamine receptor D1 promote tumor growth in human hepatocellular carcinoma.
Yan Y; Pan J; Chen Y; Xing W; Li Q; Wang D; Zhou X; Xie J; Miao C; Yuan Y; Zeng W; Chen D
Cancer Commun (Lond); 2020 Dec; 40(12):694-710. PubMed ID: 33017522
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
